← All articles

COVID-19 Vaccine Information for Rheumatology Patients

Tryon Medical Partners rheumatology team has received new recommendations from the American College of Rheumatology about how patients with rheumatic conditions should handle their medications ​when getting the COVID-19 vaccine.

Below is an alphabetical listing of common rheumatology prescription drugs, and whether or not patients should stop taking them immediately before or after getting their COVID-19 vaccine. If a drug is not listed, general guidance is that no modifications are needed.

This information is applicable for all currently available COVID-19 vaccines. Please know these are general guidelines and do not replace the clinical counsel of your individual physician.

  • Actemra: No modifications recommended
  • Anti-TNF: No modifications recommended
  • Leflunomide: No modifications recommended
  • Plaquenil: No modifications recommended
  • Prednisone: No modifications recommended
  • Sulfasalazine: No modifications recommended
  • Methotrexate: Hold for one week after COVID 19 vaccine
  • Orencia IV:  Time vaccine administration so that the first vaccination will occur four weeks after the last Orencia infusion, and postpone the subsequent ​Orencia (abatacept) infusion by one week (i.e. a five-week gap in total); no medication adjustment for the second vaccine dose
  • Orencia SQ ​(subcutaneous): Hold one week prior to and one week after the first COVID-19 vaccine dose (only); no interruption around the second vaccine dose
  • Rinvoq: Hold ​dose for one week after COVID 19 vaccine
  • Rituxan: Schedule the vaccination so that the series is initiated four weeks prior to the next Rituxan cycle; after vaccination delay Rituxan two to four weeks after the second dose, if disease activity allows
  • Xeljanz: Hold ​dose for one week after COVID 19 vaccine